Get the Stockscreener App
1.3605
3.41%
0.0405
Vincerx Pharma Inc stock is traded at $1.3605, with a volume of 71,971.
It is up +3.41% in the last 24 hours and down -67.03% over the past month.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.
See More
Previous Close:
$1.32
Open:
$1.36
24h Volume:
71,971
Relative Volume:
0.11
Market Cap:
$2.96M
Revenue:
-
Net Income/Loss:
$-48.85M
P/E Ratio:
-0.589
EPS:
-2.31
Net Cash Flow:
$-46.25M
1W Performance:
-13.61%
1M Performance:
-67.03%
6M Performance:
-87.68%
1Y Performance:
-95.16%
1-Day Range:
$1.31
$1.38
1-Week Range:
$1.31
$1.66
52-Week Range:
$1.31
$187.44
Vincerx Pharma Inc Stock (VINC) Company Profile
Name
Vincerx Pharma Inc
Sector
Industry
Phone
650-800-6676
Address
260 SHERIDAN AVENUE, PALO ALTO
Compare VINC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VINC
Vincerx Pharma Inc
|
1.365 | 2.96M | 0 | -48.85M | -46.25M | -2.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.94 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.84 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.71 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.50 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.23 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-14-22 | Initiated | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-21 | Initiated | SVB Leerink | Outperform |
| Sep-13-21 | Initiated | Laidlaw | Buy |
| Aug-25-21 | Initiated | B. Riley Securities | Buy |
Vincerx Pharma Inc Stock (VINC) Latest News
Vincerx Pharma, Inc. (NASDAQ:VINC) Sees Large Increase in Short Interest - MarketBeat
Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Rises By 1,022.5% - MarketBeat
VINC stock touches 52-week low at $1.62 amid market challenges - Investing.com Canada
Vincerx Pharma, Oqory highlight Phase 1a/1b data for OQY-3258 - TipRanks
Vincerx Pharma and Oqory reveal merger and cancer drug data - Investing.com
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - GlobeNewswire
Vincerx Pharma and Oqory reveal merger and cancer drug data By Investing.com - Investing.com UK
Revolutionary Cancer Treatment Achieves Unprecedented 80% Success Rate in Clinical Trial - StockTitan
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Vincerx Pharma enters at-the-market equity offering deal - MSN
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn
Vincerx Pharma (NASDAQ:VINC) Stock Quotes, Forecast and News Summary - Benzinga
Vincerx Pharma files for $100M mixed securities shelf - MSN
Vincerx Pharma (NASDAQ:VINC) Implements 1-for-20 Reverse Stock Split - Defense World
Palo Alto's Vincerx Pharma plans reverse stock split amid merger plans - The Business Journals
Vincerx Pharma (VINC) Stock Price, News & Analysis - MarketBeat
Vincerx Pharma announces reverse stock split; shares drop - MSN
Vincerx Pharma Inc. Announces Merger with Oqory - TipRanks
Vincerx Pharma, Inc. Announces Reverse Stock Split - The Manila Times
Vincerx Pharma Announces 1-for-20 Reverse Stock Split, Shares to Adjust January 28 - StockTitan
Vincerx Pharma enters at-the-market equity offering deal By Investing.com - Investing.com Australia
Vincerx Pharma ends sales agreement, approves reverse stock split - MSN
Vincerx Pharma ends sales agreement, approves reverse stock split By Investing.com - Investing.com Australia
VINC Stock Touches 52-Week Low at $0.17 Amid Market Challenges - Investing.com UK
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, CLBR, VINC, NEUE on Behalf of Shareholders - GlobeNewswire Inc.
Investor law firms question biotech merger's 'fairness' - The Business Journals
What Did We Find About Insider Trading At Vincerx Pharma Inc (NASDAQ: VINC)? - Stocks Register
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates VINC, MHLD, NEUE on Behalf of Shareholders - Stockhouse Publishing
VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc.VINC - Marketscreener.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VINC, NEUE, ZUO on Behalf of Shareholders - Stockhouse Publishing
Vincerx Pharma Inc (NASDAQ: VINC): On Track To A Higher Share Price - Stocks Register
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JWN, VINC, OMIC on Behalf of Shareholders - The Malaysian Reserve
$TOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the MergerVINC, VCSA, MRNS, MHLD - Markets Insider
VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders - Business Wire
Stock market today: Intrusion surged by 123.33% while Snow Lake Resources plunged by 21.88% in early trading - Business Upturn
Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish - MSN
Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket - Benzinga
Vincerx Pharma Announces Merger, Leadership Changes, and Financing - TipRanks
Vincerx Pharma To Be Acquired by Private Biotech, Cut Headcount - MarketWatch
Vincerx Pharma enters binding term sheet for merger with Oqory - TipRanks
Vincerx Pharma Inc Stock (VINC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):